Quoin reports Netherton Syndrome patient achieves near-clear skin after 12 weeks of QRX003 twice-daily

Quoin Pharmaceuticals, Ltd.

M-IASI score improved from 18 to 3; WINRS from 7 to 2; IGA from Moderate to Almost Clear after 12 weeks.
Patient satisfaction scores further improved from 6-week to 12-week mark; no safety concerns observed.
Data follows positive interim results announced Dec 2024; first subject completed full 12-week twice-daily dosing with QRX003.
Quoin is developing QRX003 for Netherton Syndrome, a rare genetic skin disorder with no approved therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.